Rockwell Medical (RMTI) Cost of Revenue (2010 - 2026)

Rockwell Medical has reported Cost of Revenue for 17 years, with the latest figure at $567000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 20.25% year-over-year to $567000.0; the trailing twelve-month figure through Mar 2026 stood at $57.4 million (up 255.83% YoY), and the FY2025 full-year result was $57.6 million, up 1993.96% from the prior year.
• Cost of Revenue for Q1 2026 stood at $567000.0, down from $55.7 million in the prior quarter.
• The five-year high for Cost of Revenue was $67.0 million in Q4 2022, with the low at -$60.2 million in Q4 2024.
• Historically, Cost of Revenue has averaged $8.4 million across 5 years, with a median of $586000.0 in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue surged 7573.54% — and 2024, when it tumbled 11231.61%.
• Rockwell Medical's Cost of Revenue stood at $67.0 million in 2022, then slumped by 99.19% to $541000.0 in 2023, then plunged by 11231.61% to -$60.2 million in 2024, then jumped by 192.57% to $55.7 million in 2025, then slumped by 98.98% to $567000.0 in 2026.
• The last three Cost of Revenue figures came in at $567000.0 (Q1 2026), $55.7 million (Q4 2025), and $531000.0 (Q3 2025), per Business Quant data.